{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nozaki S"],"funding":["Japan Agency for Medical Research and Development"],"pagination":["1961"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9898523"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Several limitations of [<sup>18</sup>F]FDG have been reported, such as nonspecific uptake of inflammation foci. Moreover, [<sup>11</sup>C]MET has been found to accumulate in normal and inflammatory tissues as well as tumors. To increase specificity to tumor tissues, PET probes with tumor-specific molecular targets have been actively developed. [<sup>18</sup>F]FIMP was found to be highly accumulated in LAT1-positive tumors but not in inflamed tissue. The aim of this study was to explore whether [<sup>18</sup>F]FIMP can be used for the early-phase evaluation of radiotherapy accompanied by inflammation, and compare its effectiveness with those of [<sup>11</sup>C]MET and [<sup>18</sup>F]FDG. Tumor uptake of [<sup>18</sup>F]FIMP decreased at day 1 after irradiation, and remained low until day 14. Comparatively, that of [<sup>18</sup>F]FDG initially decreased at day 3 but was transiently elevated at day 7 and then decreased again at day 10. Decreased tumor uptake of [<sup>11</sup>C]MET was observed at day 10. In line with the uptake of [<sup>18</sup>F]FIMP, the ratio of Ki-67 immuno-positive cells in tumor tissues significantly decreased at day 1, 7, and 10 as compared with that in the control. These findings suggest that [<sup>18</sup>F]FIMP may be a PET probe involved in the early detection and prediction of radiotherapy efficacy, although further clarification is needed."],"journal":["Scientific reports"],"pubmed_title":["Comparison of [<sup>18</sup>F]FIMP, [<sup>11</sup>C]MET, and [<sup>18</sup>F]FDG PET for early-phase assessment of radiotherapy response."],"pmcid":["PMC9898523"],"funding_grant_id":["JP16cm0106201","JP16cm0106404"],"pubmed_authors":["Doi H","Watanabe Y","Mawatari A","Hayashinaka E","Wada Y","Nozaki S","Shibata N","Nakatani Y","Hume WE"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of [<sup>18</sup>F]FIMP, [<sup>11</sup>C]MET, and [<sup>18</sup>F]FDG PET for early-phase assessment of radiotherapy response.","description":"Several limitations of [<sup>18</sup>F]FDG have been reported, such as nonspecific uptake of inflammation foci. Moreover, [<sup>11</sup>C]MET has been found to accumulate in normal and inflammatory tissues as well as tumors. To increase specificity to tumor tissues, PET probes with tumor-specific molecular targets have been actively developed. [<sup>18</sup>F]FIMP was found to be highly accumulated in LAT1-positive tumors but not in inflamed tissue. The aim of this study was to explore whether [<sup>18</sup>F]FIMP can be used for the early-phase evaluation of radiotherapy accompanied by inflammation, and compare its effectiveness with those of [<sup>11</sup>C]MET and [<sup>18</sup>F]FDG. Tumor uptake of [<sup>18</sup>F]FIMP decreased at day 1 after irradiation, and remained low until day 14. Comparatively, that of [<sup>18</sup>F]FDG initially decreased at day 3 but was transiently elevated at day 7 and then decreased again at day 10. Decreased tumor uptake of [<sup>11</sup>C]MET was observed at day 10. In line with the uptake of [<sup>18</sup>F]FIMP, the ratio of Ki-67 immuno-positive cells in tumor tissues significantly decreased at day 1, 7, and 10 as compared with that in the control. These findings suggest that [<sup>18</sup>F]FIMP may be a PET probe involved in the early detection and prediction of radiotherapy efficacy, although further clarification is needed.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2024-11-19T23:21:31.448Z","creation":"2024-11-19T23:21:31.448Z"},"accession":"S-EPMC9898523","cross_references":{"pubmed":["36737550"],"doi":["10.1038/s41598-023-29166-y"]}}